Here are four notes:
1. NICE recommends infliximab and certolizumab pegol for ankylosing spondylitis.
2. Adalimumab, certolizumab pegol and etanercept are suggested for non-radiographic axial spondyloarthritis.
3. These recommendations represent NICE’s draft guidance, not its final suggestions.
4. The Association of the British Pharmaceutical Industry appreciated the recommendations, as rheumatoid arthritis patients in the country receive limited access to biologic medicines.
More articles on spine:
Florida pain physician acquitted of murder, found guilty of minor drug charge — 5 key points
Defining value in spine: Improved outcomes & cost reduction
5 key notes on how smoking impacts cervical myelopathy treatment
